KRAS is proto-oncogene corresponding to the oncogene first identified in Kirsten rat sarcoma virus,, and the gene product was first found as a p21 GTPase. Kyowa Hakko Kirin works on a nucleic acid medicine in which siRNA, targeting KRAS, is targeted to tumor-specific unique lipid nanoparticles (LNP), and has confirmed potent antitumor effects in animal experiments.
Publication at AsiaTides meeting, Kyoto, on February 28, 2018
Kyowa Kirin develops nucleic acid drug for KRAS using proprietary liquid nanoparticles